Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript

Innate Pharma (IPHA) announced a strategic refocus during its H1 2025 earnings call, prioritizing three clinical assets: IPH4502 (Nectin-4 ADC), lacutamab (anti-KIR3DL2 antibody), and the AstraZeneca-partnered monalizumab (anti-NKG2A checkpoint inhibitor), while streamlining its organization. IPH4502's Phase I data is expected in H1 2026, lacutamab, which holds FDA Breakthrough Therapy Designation for Sézary syndrome, is slated for Phase III initiation in 2026 with potential accelerated approval in 2027, pending financing, and monalizumab's Phase III data is anticipated in H2 2026. The company reported EUR 70.4 million in cash, providing a runway until Q3 2026, reflecting a concentrated effort on these high-value programs to drive shareholder value and capitalize on near-term catalysts.

Analysis

Innate Pharma is executing a significant strategic pivot, concentrating all investment and operational focus on three core clinical assets: the AstraZeneca-partnered monalizumab, the wholly-owned lacutamab, and the next-generation ADC IPH4502. This restructuring, which includes de-prioritizing the ANKET platform and reducing headcount, extends the company's cash runway of EUR 70.4 million to the end of Q3 2026. The most advanced asset, monalizumab, faces a major catalyst with Phase III PACIFIC-9 data expected in H2 2026, which could unlock up to $825 million in remaining milestones plus significant royalties from AstraZeneca. Lacutamab has emerged as a key value driver, bolstered by an FDA Breakthrough Therapy Designation and strong Phase II data in Sézary syndrome (42.9% ORR post-mogamulizumab), with management now citing U.S. claims data suggesting a much larger addressable CTCL market than previously estimated. However, the initiation of its pivotal Phase III trial in 2026 is critically contingent on securing new financing or a partnership. The earlier-stage IPH4502 asset represents a differentiated Nectin-4 ADC designed to overcome the limitations of PADCEV, with preclinical data showing activity in resistant models; its first clinical data readout in H1 2026 will be a key validation point for the company's ADC pipeline.

Key Decisions for Investors

• Investors should monitor two key catalysts that define the company's near-term value: the Phase III PACIFIC-9 data for the AstraZeneca-partnered monalizumab in H2 2026 and the initial Phase I data for IPH4502 in H1 2026.
• The initiation of the lacutamab Phase III trial is the primary gating item for its value realization; the outcome of the company's search for financing or a partnership is a critical watchpoint, as a dilutive capital raise versus a favorable partnership will have materially different impacts on valuation.
• The stated cash runway to Q3 2026 is sufficient to reach the monalizumab and IPH4502 data readouts, but does not cover the lacutamab Phase III trial, making successful business development or financing a necessity within the next 12-18 months.
• Consider re-evaluating the terminal value of lacutamab, as management's new market analysis points to a significantly larger patient population in CTCL, which could justify improved partnership terms or a higher valuation if the financing risk is resolved.